The clinical, electrocardiographic, and scintigraphic effects of oral administration of nisoldipine were investigated using two separate study protocols. In the first, the acute effects of nisoldipine were evaluated by means of nuclear ventricolography and demonstrated no deleterious effects on global contractility and an amelioration of several hypokinetic segments. In the second protocol, myocardial perfusion effects were evaluated by means of tomoscintigraphy. An improvement of segmental uptake of thallium was caused by nisoldipine. The addition of atenolol markedly reduced the rate-pressure product and further improved myocardial perfusion.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Corrigendum: Inhibitory effects of calcium channel blockers nisoldipine and nimodipine on ivacaftor metabolism and their underlying mechanism.
Front Pharmacol
September 2024
First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
[This corrects the article DOI: 10.3389/fphar.2024.
View Article and Find Full Text PDFInhibitory effects of calcium channel blockers nisoldipine and nimodipine on ivacaftor metabolism and their underlying mechanism.
Front Pharmacol
September 2024
The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Ivacaftor is the first potentiator of the cystic fibrosis transmembrane conductance regulator (CFTR) protein approved for use alone in the treatment of cystic fibrosis (CF). Ivacaftor is primarily metabolized by CYP3A4 and therefore may interact with drugs that are CYP3A4 substrates, resulting in changes in plasma exposure to ivacaftor. The study determined the levels of ivacaftor and its active metabolite M1 by ultra performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS).
View Article and Find Full Text PDFDetermination of nine cardiovascular drugs in human plasma by QuEChERS-UPLC-MS/MS.
Heliyon
December 2023
Hebei Institute of Drug and Medical Device Inspection, Shijiazhuang 050000, China.
To determine the concentrations of nine drugs used in the treatment of cardiovascular diseases in human plasma through QuEChERS pre-treatment combined with ultra-performance liquid chromatography-tandem mass spectrometry. Plasma samples were extracted with 3 mL of acetonitrile, 400 mg of anhydrous magnesium sulfate as a salting agent, and 20 mg of C18 as a sorbent. An Agilent Poroshell 120 EC-C18 column (4.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!